Key Highlights
- Scienture Holdings shares fell 60.30% over one month to $2.80 as of Friday, October 23, 2026.
- The stock lost 17.18% over one week and gained 1.05% on the day.
- A 1-for-25 reverse split cut shares to about 1.64 million from 41.06 million, effective October 5.
- Preliminary third-quarter revenue was about $1.22 million, up 256% sequentially, against estimates of $1.58 million.
- The shares closed down 17.14% on October 13, the day of the revenue release.
Scienture Holdings: Why Did the Stock Fall 60.30% in a Month?
Scienture Holdings (NASDAQ:SCNX) was priced at $2.80 on Friday, October 23, 2026, a penny stock down 60.30% over one month, 17.18% over one week and up 1.05% on the day. Calculated from the screen, the price was near $7.05 a month earlier. Commercial Services rose 9.85% over the month, so the stock trailed its group by about 70 percentage points, calculated.
Three company events fell in the window: a reverse split announced on September 30, a formulary announcement on October 2 and preliminary third-quarter revenue on October 13. The shares closed down 31.83%, 10.33% and 17.14% on those days.
Reverse Split: Why Did the Company Consolidate Shares?
On September 30 the company announced a 1-for-25 reverse split, effective before the market opened on October 5, to help meet Nasdaq's minimum bid price. Shares outstanding fell from 41,064,146 to about 1,642,565, and authorized shares were unchanged. The stock closed down 31.83% on the announcement.
At the $2.80 screen price and 1.64 million shares, the market value is about $4.6 million, calculated, against stockholders' equity of $64.1 million at June 30. Equity at that level is about 14 times the market value, calculated.
Third-Quarter Revenue: Why Did Growth of 256% Not Satisfy the Market?
On October 13 the company reported unaudited preliminary third-quarter revenue of about $1.22 million, up 256% from about $344,000 in the second quarter. Wholesale unit sales of Arbli rose 74% sequentially. Market estimates stood at $1.58 million, so revenue came in about 23% short, calculated.
The company targets profitability in 2027 and full results will appear in its quarterly filing. The stock closed down 17.14% that day and fell 13.10% on October 19.
Products and Cash: What Do Arbli and Rezenopy Add?
Scienture develops and sells specialty pharmaceutical products, led by Arbli, a losartan oral suspension, and Rezenopy, a naloxone nasal spray launched commercially in the second quarter. Second-quarter results showed revenue of $343,639, an operating loss of $2.70 million and a net loss of $2.82 million. The company held about $11.2 million of cash and restricted cash at June 30, with notes payable of about $10.7 million.
On September 22 an exclusive distribution agreement for Rezenopy gave access to about 2,000 opioid treatment program clinics. On October 2 Arbli was added to formularies at three U.S. pediatric academic medical centers, and the stock closed down 10.33%. Patent coverage is expected to extend through 2041.
What to Watch for Scienture Holdings After the Split?
Next results are expected around November 12. Followers will track Arbli and Rezenopy sales against the $1.22 million quarterly base, the cash position against notes payable and whether the post-split price stays above Nasdaq's bid threshold.






Please wait processing your request...